A Phase 1 interventional study of HMPL-523 in Non Hodgkin Lymphoma, sponsored by Hutchmed. Terminated at 32 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Hutchmed · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Lymphoma, Non-Hodgkin with a site in Spain — 21 open to participants now, 51 under way, 13 of them phase 3. Lymphoma, Non-Hodgkin · Spain.
Among the 158 studies in Lymphoma, Non-Hodgkin with a site in Spain, this one is the 109th largest by enrollment of the 156 interventional ones that give a count, is one of 18 that started in 2019, is one of 48 in phase 1, and was the 85th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →21 of the 158 studies in Lymphoma, Non-Hodgkin with a site in Spain are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Spain, United States, Australia and 5 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Australia and 9 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, France and 5 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Spain, Australia, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 62 · Phase 3 44 · Phase 4 5
First in 1999; this study’s year is marked. 18 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 138 across the 156 interventional studies, 96 across the 1 observational. Of the 102 that completed or were terminated, 62 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
146 of 158 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hutchmed, one of the names counted as HUTCHMED. Under that name alone:
Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
HUTCHMED has 2 studies filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
18 of the studies in Lymphoma, Non-Hodgkin with a site in Spain that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02972840Phase 3Acerta Pharma BVA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | 2027-02-15 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
Add all 18 to your calendar (.ics) → With an account.
Among the 158 studies in Lymphoma, Non-Hodgkin with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).
Dose Escalation Stage (Stage 1)
Dosing will begin at 100 mg once daily (QD). A cycle of study treatment will be defined as 28 days of continuous dosing. The modified 3+3 design will be applied for dose escalation and MTD determination to limit the number of patients exposed to potentially ineffective or unsafe doses. The study will enroll 1 patient and the patient will be treated for a 28-day cycle in the initial dose cohort. If there is no Dose Limiting Toxicity (DLT) and no more than 2 treatment-emergent adverse events (TEAEs) of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 in the first treatment cycle, the study will be escalated to the next dose cohort and continue with the standard 3+3 design. Otherwise, the trial will revert to a standard 3+3 design from the initial dose cohort. A minimum of 3 patients will be enrolled and observed for toxicity in each successive dose cohort after the initial dose cohort. If the 3 patients initially enrolled in a given dose cohort complete the DLT assessment window (Cycle 1, Days 1-28) without experiencing a DLT, 3 patients will be enrolled at the next higher dose level. If 2 or more of the initial 3 patients enrolled at any dose level experience a DLT during the DLT assessment window, the dose escalation will be halted. If 1 of the initial 3 patients enrolled at any dose level experiences a DLT during the DLT assessment window, additional patients will be enrolled at that dose level for a minimum of 6 evaluable patients for DLT. If a DLT is observed in 1 of the 6 valuable patients at this dose level, dose escalation will proceed to the next pre- defined dose level. If DLTs are observed in 2 or more of the 6 evaluable patients at a given dose level, the dose escalation will be halted. If the dose escalation is completed due to 2 or more DLTs at a dose level and that dose level is ≥50% higher than the previous dose level, then an intermediate dose level may be evaluated for toxicity in the same manner as described above. If the dose level is \<50% higher than the previous dose level, in which only 3 DLT evaluable patients were enrolled, 3 additional patients will be enrolled at that dose level to comprise 6 DLT evaluable patients.
The proposed dose escalation scheme comprises Cohorts 1 to 5 with dosing levels of 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD and 800 mg QD, respectively. The need for dose escalation beyond 800 mg QD, the specific dose to be tested and the potential for twice-daily (BID) dosing will be evaluated jointly by investigators and the sponsor based on the cumulative clinical safety, pharmacokinetic, and preliminary efficacy data. Safety monitoring and evaluation of dose escalation will be carried out by the Safety Review Committee, which will be comprised of the sponsor's study team members (including medical monitor, safety monitor and and Pharmacokinetic scientist) and the site principal investigators. The adverse event profile and serum concentration of HMPL-523 data will be evaluated to determine whether it is safe to continue the assigned HMPL-523 dose for dose escalation or whether the dose should be de-escalated to the lower dose level.
Dose Expansion Stage (Stage 2)
The adverse event profile, serum concentration, and preliminary anti-tumor activity of HMPL-523 at the maximum tolerated dose(MTD)/recommended phase 2 dose(RP2D) will be further evaluated in approximately 50 patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphomas. The tumor types of the dose expansion stage are restricted to:
Patients will receive HMPL-523 at the MTD/RP2D for continuous 28-day treatment cycles until disease progression, death, intolerable toxicity, at investigator's discretion that the patient can no longer benefit from the study treatment, patient withdrawal from the study, or the end of study, whichever comes first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet the following criteria to be eligible for study entry:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients to received study drug (HMPL-523)
Drug: HMPL-523
Oral HMPL-523
Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)
A DLT was defined as the occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless clearly unrelated to the study treatment. AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0: non-hematologic toxicity: all non-hematologic TEAEs of Grade 3 or greater with the exception of Grade 3 nausea or vomiting controlled by supportive therapy; hematologic toxicity: Grade 4 neutropenia \>5 days, Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or which required platelets transfusion, Grade \>=3 febrile neutropenia (defined as absolute neutrophil count \<1000/cubic millimeter with a single temperature \>38.3 degree Celsius \[°C\] or a sustained temperature of \>=38°C for more than 1 hour), Grade 4 anemia not explained by underlying disease; any TEAE that required a dose delay of \>=15 days; any case of Hy's Law.
Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation
An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. TEAEs were defined as AEs with an onset date on or after the first dose of study treatment and no later than 30 days after the date of last study treatment administration or start of a new treatment of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were the TEAEs that were reported as related to study treatment by the Investigator.
Time frame: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months
Dose Escalation Stage: Recommended Phase 2 Dose of HMPL-523
RP2D was based on the pharmacokinetics (PK), safety, and tolerability assessments in dose escalation stage patients.
Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)
Dose Expansion Stage: Objective Response Rate (ORR)
ORR:percentage of patients who had best overall response (BOR) with complete response (CR),CR with incomplete marrow recovery (CRi),nodular partial response (nPR) or PR for CLL patients; CR, very good PR(VGPR), PR or minor response(MR) for WM patients; CR or PR for patients with disease type other than CLL and WM. BOR:best response from start of treatment until progression or any further anticancer therapy.CR:absence of serum(S) monoclonal immunoglobulin (Ig)M, normal S IgM, complete resolution of extramedullary disease,morphologically normal bone marrow aspirate and trephine biopsy. CRi:criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR:patients with residual CLL cells. PR, VGPR, MR:detectable monoclonal IgM,no new signs/symptoms of active disease and PR:\>=50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Expansion Stage: Complete Response Rate
CR rate was defined as the percentage of patients who had BOR with CR or CRi for CLL patients, and CR only for other patients. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. CR was defined as the absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi was defined as the criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Expansion Stage: Clinical Benefit Rate (CBR)
CBR was defined as the percentage of patients who had BOR of stable disease (SD) or better. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. SD was defined as detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Expansion Stage: Duration of Response (DOR)
DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L, and MR) was achieved until earlier of first documentation of definitive PD or death from any cause. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR,MR:detectable monoclonal IgM,no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM,complete resolution of extramedullary disease,MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to disease.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Expansion Stage: Time to Response (TTR)
TTR was defined as the time from the first dose of study treatment to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in serum IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in serum IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in serum IgM. Kaplan Meier analysis included only the responders.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Expansion Stage: Progression-Free Survival (PFS)
PFS was defined as the time from the date of first study treatment to the earliest date of PD or death due to any reason whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to disease.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Escalation Stage and Dose Expansion Stage: Maximum Plasma Concentration (Cmax) of HMPL-523
Blood samples were collected to determine Cmax of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Time to Reach Maximum Plasma Concentration (Tmax) of HMPL-523
Blood samples were collected to determine tmax of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve From Time Zero (Pre-Dose) to Time of Last Quantifiable Concentration (AUC0-t) of HMPL-523
Blood samples were collected to determine AUC0-t of HMPL-523. The PK parameters were determined by non-compartmental analysis.
Time frame: Dose escalation and dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 1 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of HMPL-523
Blood samples were collected to determine AUCtau of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1, 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 1 and 28 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Apparent Systemic Clearance (CL/F) of HMPL-523
Blood samples were collected to determine CL/F of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Minimum Plasma Concentration (Cmin) of HMPL-523
Blood samples were collected to determine Cmin of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Ratio of Metabolite to Parent Maximum Plasma Concentration (MRCmax)
Blood samples were collected to determine MRCmax. The metabolites of HMPL-523 were M1 (HM5023222) and M44 (HM5025866) only. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Ratio of Metabolite to Parent Area Under the Concentration-Time Curve During a Dosing Interval (MRAUCtau)
Blood samples were collected to determine MRAUCtau. The metabolites of HMPL-523 were M1 (HM5023222) and M44 (HM5025866) only. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Accumulation Ratio for Maximum Plasma Concentration (RA[Cmax]) of HMPL-523
Blood samples were collected to determine RA(Cmax) of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Dose Escalation Stage and Dose Expansion Stage: Accumulation Ratio for Area Under the Concentration-Time Curve During a Dosing Interval (RA[AUC]) of HMPL-523
Blood samples were collected to determine RA(AUC) of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
Time frame: Dose escalation: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Days 15 and 28 of Cycle 1; Dose expansion: Pre-dose and 0.5, 1, 2, 4, 6, 8 hours post-dose on Day 28 of Cycle 1
Dose Expansion Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation
An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. TEAEs were defined as AEs with an onset date on or after the first dose of study treatment and no later than 30 days after the date of last study treatment administration or start of a new treatment of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were the TEAEs that were reported as related to study treatment by the Investigator.
Time frame: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months
Dose Escalation Stage: Objective Response Rate
ORR: percentage of patients who had BOR with CR, CRi, nPR or PR for CLL patients; CR, VGPR, PR or MR for WM patients; CR or PR for patients with disease type other than CLL and WM. BOR: best response from start of treatment until progression or any further anticancer therapy. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Escalation Stage: Complete Response Rate
CR rate was defined as the percentage of patients who had BOR with CR or CRi for CLL patients, and CR only for other patients. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. CR was defined as the absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi was defined as the criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Escalation Stage: Clinical Benefit Rate
CBR was defined as the percentage of patients who had BOR of SD or better. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. SD was defined as detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Escalation Stage: Duration of Response
DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L, and MR) was achieved until earlier of first documentation of definitive PD or death from any cause. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to disease.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Escalation Stage: Time to Response
TTR was defined as the time from the first dose of study treatment to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. Kaplan Meier analysis included only the responders.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Dose Escalation Stage: Progression-Free Survival
PFS was defined as the time from the date of first study treatment to the earliest date of PD or death due to any reason whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to disease.
Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
This Phase 1 open-label study was conducted in patients with relapsed or refractory lymphoma who had exhausted approved therapy options. Study recruitment was terminated based on a strategic decision made by the Sponsor to discontinue development of HMPL-523 for lymphoma in the United States, Europe, and Australia with no safety concerns.
| Milestone | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 4 | 4 | 25 | 1 | 7 | 2 | 1 | 1 | 2 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 3 | 3 | 3 | 4 | 4 | 25 | 1 | 7 | 2 | 1 | 1 | 2 | 9 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 3 | 2 | 2 | 1 | 2 | 1 | 13 | 0 | 2 | 0 | 1 | 0 | 0 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 3 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 0 | 5 | 1 | 3 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Anti-neoplasm treatment | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A DLT was defined as the occurrence of any of the following treatment-emergent adverse events (TEAEs) during the DLT assessment window, unless clearly unrelated to the study treatment. AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0: non-hematologic toxicity: all non-hematologic TEAEs of Grade 3 or greater with the exception of Grade 3 nausea or vomiting controlled by supportive therapy; hematologic toxicity: Grade 4 neutropenia \>5 days, Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or which required platelets transfusion, Grade \>=3 febrile neutropenia (defined as absolute neutrophil count \<1000/cubic millimeter with a single temperature \>38.3 degree Celsius \[°C\] or a sustained temperature of \>=38°C for more than 1 hour), Grade 4 anemia not explained by underlying disease; any TEAE that required a dose delay of \>=15 days; any case of Hy's Law.
| Participants | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD |
|---|---|---|---|---|---|---|
| Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs) | 1 | 0 | 0 | 0 | 0 | 2 |
An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. TEAEs were defined as AEs with an onset date on or after the first dose of study treatment and no later than 30 days after the date of last study treatment administration or start of a new treatment of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were the TEAEs that were reported as related to study treatment by the Investigator.
| Participants | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD |
|---|---|---|---|---|---|---|
| Any TEAE | 4 | 3 | 3 | 3 | 4 | 4 |
| Any Treatment related TEAE | 3 | 3 | 3 | 3 | 3 | 3 |
| Any TEAE leading to treatment interruption | 1 | 2 | 1 | 2 | 2 | 2 |
| Any TEAE leading to treatment reduction | 0 | 0 | 0 | 0 | 0 | 3 |
| Any TEAE leading to treatment discontinuation | 0 | 0 | 0 | 0 | 1 | 2 |
RP2D was based on the pharmacokinetics (PK), safety, and tolerability assessments in dose escalation stage patients.
| mg | Dose Escalation Stage: HMPL-523 |
|---|---|
| Dose Escalation Stage: Recommended Phase 2 Dose of HMPL-523 | 700 |
ORR:percentage of patients who had best overall response (BOR) with complete response (CR),CR with incomplete marrow recovery (CRi),nodular partial response (nPR) or PR for CLL patients; CR, very good PR(VGPR), PR or minor response(MR) for WM patients; CR or PR for patients with disease type other than CLL and WM. BOR:best response from start of treatment until progression or any further anticancer therapy.CR:absence of serum(S) monoclonal immunoglobulin (Ig)M, normal S IgM, complete resolution of extramedullary disease,morphologically normal bone marrow aspirate and trephine biopsy. CRi:criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR:patients with residual CLL cells. PR, VGPR, MR:detectable monoclonal IgM,no new signs/symptoms of active disease and PR:\>=50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM.
| percentage of patients | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|
| Dose Expansion Stage: Objective Response Rate (ORR) | 24.0 (9.4 to 45.1) | 100 (2.5 to 100.0) | 28.6 (3.7 to 71.0) | 0 (0.0 to 84.2) | 0 (0.0 to 97.5) | 100 (2.5 to 100.0) | 0 (0.0 to 97.5) | 37.5 (8.5 to 75.5) |
CR rate was defined as the percentage of patients who had BOR with CR or CRi for CLL patients, and CR only for other patients. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. CR was defined as the absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi was defined as the criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia.
| percentage of patients | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|
| Dose Expansion Stage: Complete Response Rate | 8.0 (1.0 to 26.0) | 100 (2.5 to 100.0) | 0 (0.0 to 41.0) | 0 (0.0 to 84.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) | 25.0 (3.2 to 65.1) |
CBR was defined as the percentage of patients who had BOR of stable disease (SD) or better. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. SD was defined as detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.
| percentage of patients | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|
| Dose Expansion Stage: Clinical Benefit Rate (CBR) | 64.0 (42.5 to 82.0) | 100 (2.5 to 100.0) | 71.4 (29.0 to 96.3) | 100 (15.8 to 100.0) | 100 (2.5 to 100.0) | 100 (2.5 to 100.0) | 0 (0.0 to 97.5) | 37.5 (8.5 to 75.5) |
DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L, and MR) was achieved until earlier of first documentation of definitive PD or death from any cause. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR,MR:detectable monoclonal IgM,no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM,reduction in extramedullary disease,VGPR: \>=90% reduction in S IgM,complete resolution of extramedullary disease,MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to disease.
| months | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|
| Dose Expansion Stage: Duration of Response (DOR) | 6.7 (1.9 to NA) | NA (NA to NA) | 11.3 (10.6 to NA) | — | — | NA (NA to NA) | — | 5.7 (2.0 to NA) |
TTR was defined as the time from the first dose of study treatment to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in serum IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in serum IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in serum IgM. Kaplan Meier analysis included only the responders.
| months | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|
| Dose Expansion Stage: Time to Response (TTR) | 1.9 (1.4 to NA) | 24.8 (NA to NA) | 1.8 (1.7 to NA) | — | — | 6.1 (NA to NA) | — | 1.8 (1.4 to NA) |
PFS was defined as the time from the date of first study treatment to the earliest date of PD or death due to any reason whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to disease.
| months | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|
| Dose Expansion Stage: Progression-Free Survival (PFS) | 3.6 (1.7 to 4.8) | NA (NA to NA) | 12.3 (1.7 to NA) | NA (NA to NA) | 5.1 (NA to NA) | NA (NA to NA) | 1.4 (NA to NA) | 1.8 (0.8 to 7.2) |
Blood samples were collected to determine Cmax of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.
| nanograms per milliliter (ng/mL) | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 36.43 ± 33.98 | 51.93 ± 10.45 | 58.00 ± 19.24 | 109.3 ± 11.55 | 126.3 ± 45.55 | 208.5 ± 115.9 | 173.1 ± 106.5 | 131.8 ± 61.33 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 150.0 ± 71.30 |
| Cycle 1 Day 15 | 32.53 ± 14.00 | 52.27 ± 10.90 | 118.1 ± 49.25 | 233.7 ± 42.83 | 218.0 ± 37.16 | NA ± NA | — | — | — | — | — | — | — |
| Cycle 1 Day 28 | 36.10 ± 13.08 | 52.70 ± 12.30 | 104.7 ± 19.55 | 169.3 ± 67.28 | 249.7 ± 59.72 | NA ± NA | 229.0 ± 113.7 | 195.5 ± 153.6 | NA ± NA | — | NA ± NA | NA ± NA | 240.7 ± 84.51 |
Blood samples were collected to determine tmax of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.
| hour (h) | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 5.84 (2.00 to 6.00) | 5.92 (4.00 to 5.98) | 5.80 (4.02 to 7.75) | 3.83 (1.07 to 7.75) | 4.09 (4.00 to 6.00) | 6.02 (1.00 to 6.05) | 4.00 (1.00 to 6.03) | 2.17 (1.00 to 6.00) | NA (1.98 to 4.17) | NA (23.50 to 23.50) | NA (4.00 to 4.00) | NA (4.00 to 4.00) | 4.00 (2.00 to 7.52) |
| Cycle 1 Day 15 | 5.00 (2.00 to 7.83) | 4.98 (2.00 to 6.00) | 3.90 (2.02 to 5.92) | 3.98 (1.95 to 4.00) | 4.22 (4.08 to 5.83) | NA (6.00 to 6.00) | — | — | — | — | — | — | — |
| Cycle 1 Day 28 | 5.92 (4.00 to 8.00) | 6.00 (4.08 to 6.02) | 4.00 (2.00 to 6.12) | 4.20 (2.02 to 6.00) | 5.78 (3.98 to 5.98) | NA (1.83 to 1.83) | 4.03 (2.00 to 7.97) | 4.93 (2.08 to 24.17) | NA (6.17 to 6.17) | — | NA (8.00 to 8.00) | NA (2.00 to 2.00) | 4.10 (4.00 to 25.33) |
Blood samples were collected to determine AUC0-t of HMPL-523. The PK parameters were determined by non-compartmental analysis.
| ng*h/mL | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation Stage and Dose Expansion Stage: Area Under the Concentration-Time Curve From Time Zero (Pre-Dose) to Time of Last Quantifiable Concentration (AUC0-t) of HMPL-523 | 352.3 ± 247.5 | 589.1 ± 77.22 | 734.1 ± 195.0 | 1278 ± 50.63 | 1608 ± 469.1 | 2624 ± 1244 | 1771 ± 864.5 | 1568 ± 676.6 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 1622 ± 686.5 |
Blood samples were collected to determine AUCtau of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
| ng*h/mL | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 352.3 ± 247.5 | 589.1 ± 77.22 | NA ± NA | 1278 ± 50.63 | 1608 ± 469.1 | 2624 ± 1244 | 1759 ± 886.3 | 1568 ± 43.1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 1622 ± 686.5 |
| Cycle 1 Day 15 | 457.4 ± 184.9 | NA ± NA | 1346 ± 382.8 | 2618 ± 864.3 | 3291 ± 679.7 | NA ± NA | — | — | — | — | — | — | — |
| Cycle 1 Day 28 | 562.5 ± 193.4 | 765.1 ± 150.9 | 1298 ± 341.2 | NA ± NA | 3832 ± 1080 | — | 3324 ± 1735 | 2848 ± 1929 | NA ± NA | — | NA ± NA | NA ± NA | 3621 ± 1273 |
Blood samples were collected to determine CL/F of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
| Liter/h | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 15 | 249.3 ± 101.3 | NA ± NA | 313.3 ± 85.63 | 247.8 ± 86.15 | 219.8 ± 51.17 | NA ± NA | — | — | — | — | — | — | — |
| Cycle 1 Day 28 | 190.8 ± 56.92 | 269.2 ± 59.18 | 321.2 ± 74.49 | NA ± NA | 194.9 ± 65.24 | — | 275.0 ± 142.3 | 360.9 ± 220.8 | NA ± NA | — | NA ± NA | NA ± NA | 213.1 ± 71.20 |
Blood samples were collected to determine Cmin of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
| ng/mL | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 15 | 11.07 ± 6.639 | 10.64 ± 3.688 | 26.17 ± 11.35 | 39.44 ± 39.48 | 60.90 ± 18.07 | NA ± NA | — | — | — | — | — | — | — |
| Cycle 1 Day 28 | 10.51 ± 2.327 | 12.23 ± 1.102 | 30.10 ± 17.30 | 40.10 ± 27.92 | 65.80 ± 24.68 | — | 66.09 ± 45.04 | 60.40 ± 42.23 | NA ± NA | — | NA ± NA | NA ± NA | 62.23 ± 22.62 |
Blood samples were collected to determine MRCmax. The metabolites of HMPL-523 were M1 (HM5023222) and M44 (HM5025866) only. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.
| ratio | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M1: Cycle 1 Day 15 | 0.5991 ± 0.2933 | 0.7537 ± 0.4587 | 0.7159 ± 0.3763 | 0.5895 ± 0.1236 | 0.8991 ± 0.3522 | NA ± NA | — | — | — | — | — | — | — |
| M1: Cycle 1 Day 28 | 0.4787 ± 0.2675 | 0.5856 ± 0.1012 | 0.7050 ± 0.4432 | 0.6903 ± 0.04638 | 0.8849 ± 0.3142 | NA ± NA | 0.7690 ± 0.3010 | 0.6421 ± 0.2987 | NA ± NA | — | NA ± NA | NA ± NA | 0.5671 ± 0.3079 |
| M44: Cycle 1 Day 15 | 0.8269 ± 0.6184 | 0.5329 ± 0.3303 | 0.3375 ± 0.2551 | 0.2984 ± 0.08007 | 0.1643 ± 0.02048 | NA ± NA | — | — | — | — | — | — | — |
| M44: Cycle 1 Day 28 | 1.348 ± 1.066 | 0.6394 ± 0.4393 | 0.2326 ± 0.1265 | 0.3579 ± 0.1291 | 0.1981 ± 0.08459 | NA ± NA | 0.3582 ± 0.3226 | 0.5167 ± 0.4552 | NA ± NA | — | NA ± NA | NA ± NA | 0.6787 ± 0.8715 |
Blood samples were collected to determine MRAUCtau. The metabolites of HMPL-523 were M1 (HM5023222) and M44 (HM5025866) only. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
| ratio | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M1: Cycle 1 Day 15 | 0.6036 ± 0.2634 | NA ± NA | 0.6525 ± 0.3439 | 0.5678 ± 0.08923 | 0.7382 ± 0.2924 | NA ± NA | — | — | — | — | — | — | — |
| M1: Cycle 1 Day 28 | 0.5254 ± 0.2937 | 0.6092 ± 0.1196 | 0.6441 ± 0.3541 | NA ± NA | 0.7391 ± 0.2139 | — | 0.7104 ± 0.2589 | 0.5776 ± 0.2271 | NA ± NA | — | NA ± NA | NA ± NA | 0.5219 ± 0.2584 |
| M44: Cycle 1 Day 15 | 0.3717 ± 0.2715 | NA ± NA | 0.1610 ± 0.1124 | 0.1691 ± 0.06730 | 0.08454 ± 0.03028 | NA ± NA | — | — | — | — | — | — | — |
| M44: Cycle 1 Day 28 | 0.5559 ± 0.5738 | 0.2030 ± 0.06731 | 0.1573 ± 0.1300 | NA ± NA | 0.09547 ± 0.03969 | — | 0.2145 ± 0.1807 | 0.2147 ± 0.1247 | NA ± NA | — | NA ± NA | NA ± NA | 0.2864 ± 0.2716 |
Blood samples were collected to determine RA(Cmax) of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose expansion stage: MZL arm.
| ratio | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 15 | 1.187 ± 0.5408 | 1.020 ± 0.1992 | 2.126 ± 0.7567 | 2.151 ± 0.4241 | 1.468 ± 0.2829 | NA ± NA | — | — | — | — | — | — | — |
| Cycle 1 Day 28 | 1.579 ± 1.148 | 1.065 ± 0.3991 | 1.982 ± 0.8350 | 1.558 ± 0.6234 | 1.683 ± 0.4367 | NA ± NA | 1.488 ± 0.5440 | 1.955 ± 0.4608 | NA ± NA | — | NA ± NA | NA ± NA | 1.917 ± 1.229 |
Blood samples were collected to determine RA(AUC) of HMPL-523. The PK parameters were determined by non-compartmental analysis. Eventually, the patients discontinued as they progressed in the study. Hence, fewer patients at each cycle and no patients returned on Cycle 1 Day 28 in dose escalation stage: HMPL-523 800 mg QD and dose expansion stage: MZL arms.
| ratio | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL and CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 15 | 1.590 ± 0.8423 | NA ± NA | NA ± NA | 2.049 ± 0.6594 | 1.805 ± 0.3995 | NA ± NA | — | — | — | — | — | — | — |
| Cycle 1 Day 28 | 2.358 ± 1.545 | 1.305 ± 0.2577 | NA ± NA | NA ± NA | 2.102 ± 0.6167 | — | 1.855 ± 0.5961 | 2.324 ± 0.6424 | NA ± NA | — | NA ± NA | NA ± NA | 2.326 ± 0.8264 |
An AE was any untoward medical occurrence in a clinical study patient temporally associated with the use of a study treatment, whether or not considered related to the treatment. TEAEs were defined as AEs with an onset date on or after the first dose of study treatment and no later than 30 days after the date of last study treatment administration or start of a new treatment of anti-neoplasm therapy, whichever was earlier. Treatment related AEs were the TEAEs that were reported as related to study treatment by the Investigator.
| Participants | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|
| Any TEAE | 25 | 0 | 7 | 2 | 1 | 1 | 2 | 9 |
| Any Treatment related TEAE | 19 | 0 | 6 | 2 | 1 | 0 | 2 | 7 |
| Any TEAE leading to treatment interruption | 12 | 0 | 6 | 1 | 0 | 1 | 1 | 4 |
| Any TEAE leading to treatment reduction | 0 | 0 | 4 | 0 | 1 | 0 | 1 | 0 |
| Any TEAE leading to treatment discontinuation | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
ORR: percentage of patients who had BOR with CR, CRi, nPR or PR for CLL patients; CR, VGPR, PR or MR for WM patients; CR or PR for patients with disease type other than CLL and WM. BOR: best response from start of treatment until progression or any further anticancer therapy. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM.
| percentage of patients | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD |
|---|---|---|---|---|---|---|
| Dose Escalation Stage: Objective Response Rate | 0 (0.0 to 60.2) | 0 (0.0 to 70.8) | 50.0 (1.3 to 98.7) | 33.3 (0.8 to 90.6) | 33.3 (0.8 to 90.6) | 50.0 (6.8 to 93.2) |
CR rate was defined as the percentage of patients who had BOR with CR or CRi for CLL patients, and CR only for other patients. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. CR was defined as the absence of serum monoclonal IgM, normal serum IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi was defined as the criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia.
| percentage of patients | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD |
|---|---|---|---|---|---|---|
| Dose Escalation Stage: Complete Response Rate | 0 (0.0 to 60.2) | 0 (0.0 to 70.8) | 0 (0.0 to 84.2) | 33.3 (0.8 to 90.6) | 0 (0.0 to 70.8) | 50.0 (6.8 to 93.2) |
CBR was defined as the percentage of patients who had BOR of SD or better. BOR was defined as the best response from start of treatment until progression or any further anticancer therapy. SD was defined as detectable monoclonal IgM, \<25% reduction and \<25% increase in serum IgM level, no progression in extramedullary disease, no new signs/symptoms of active disease.
| percentage of patients | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD |
|---|---|---|---|---|---|---|
| Dose Escalation Stage: Clinical Benefit Rate | 0 (0.0 to 60.2) | 0 (0.0 to 70.8) | 100 (15.8 to 100.0) | 66.7 (9.4 to 99.2) | 33.3 (0.8 to 90.6) | 50.0 (6.8 to 93.2) |
DOR: time from when first response (CR, CRi, PR, nPR, VGPR, PR-L, and MR) was achieved until earlier of first documentation of definitive PD or death from any cause. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. PD: \>=25% increase in S IgM level from lowest nadir and/or progression in clinical features attributable to disease.
| months | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD |
|---|---|---|---|---|---|---|
| Dose Escalation Stage: Duration of Response | — | — | 15.7 (NA to NA) | 25.9 (NA to NA) | NA (NA to NA) | NA (NA to NA) |
TTR was defined as the time from the first dose of study treatment to the first occurrence of CR, CRi, PR, nPR, VGPR, PR-L, or MR. CR: absence of S monoclonal IgM, normal S IgM, complete resolution of extramedullary disease, morphologically normal bone marrow aspirate and trephine biopsy. CRi: criteria fulfilled for CR but persistent cytopenia, anemia, thrombocytopenia or neutropenia. nPR: patients with residual CLL cells. PR-L: patients achieved PR with CLL-related signs/symptoms other than lymphocytosis and continued on therapy. PR, VGPR, MR: detectable monoclonal IgM, no new signs/symptoms of active disease and PR: \>=50% but \<90% reduction in S IgM, reduction in extramedullary disease, VGPR: \>=90% reduction in S IgM, complete resolution of extramedullary disease, MR: \>=25% but \<50% reduction in S IgM. Kaplan Meier analysis included only the responders.
| months | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD |
|---|---|---|---|---|---|---|
| Dose Escalation Stage: Time to Response | — | — | 6.7 (NA to NA) | 1.6 (NA to NA) | 1.6 (NA to NA) | 5.2 (1.1 to NA) |
PFS was defined as the time from the date of first study treatment to the earliest date of PD or death due to any reason whichever occurred first. PD was defined as \>=25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to disease.
| months | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD |
|---|---|---|---|---|---|---|
| Dose Escalation Stage: Progression-Free Survival | 1.3 (1.3 to NA) | 1.6 (1.0 to NA) | 12.9 (3.5 to NA) | 14.7 (1.9 to NA) | 1.9 (1.7 to NA) | NA (0.9 to NA) |
Collected over AEs and SAEs were collected from the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months for each stage (dose escalation and dose expansion). All-cause mortality (deaths) were collected from first dose of study treatment (Day 1) up to end of study visit, approximately 65 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation Stage: HMPL-523 100 mg QD | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Dose Escalation Stage: HMPL-523 200 mg QD | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Escalation Stage: HMPL-523 400 mg QD | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation Stage: HMPL-523 600 mg QD | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation Stage: HMPL-523 700 mg QD | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Dose Escalation Stage: HMPL-523 800 mg QD | 1/4 (25%) | 3/4 (75%) | 4/4 (100%) |
| Dose Expansion Stage: HL | 2/25 (8%) | 6/25 (24%) | 25/25 (100%) |
| Dose Expansion Stage: CLL | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Dose Expansion Stage: CLL-post BTK | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Dose Expansion Stage: FL | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) |
| Dose Expansion Stage: MZL | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Dose Expansion Stage: LPL/WM | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Dose Expansion Stage: MCL | 1/2 (50%) | 0/2 (0%) | 2/2 (100%) |
| Dose Expansion Stage: PTCL | 3/9 (33.3%) | 5/9 (55.6%) | 9/9 (100%) |
| Event | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/4 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 1/25 | 0/1 | 0/7 | 1/2 | 0/1 | 1/1 | 0/2 | 0/9 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/25 | 0/1 | 3/7 | 1/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| Intestinal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/3 | 0/3 | 1/3 | 0/4 | 0/4 | 0/25 | 0/1 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| Atrial tachycardiaCardiac disorders | 0/4 | 1/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/25 | 0/1 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| Small intestinal obstructionGastrointestinal disorders | 0/4 | 1/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/25 | 0/1 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| Abortion spontaneous completePregnancy, puerperium and perinatal conditions | 0/4 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/25 | 0/1 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| COVID-19Infections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 1/4 | 0/25 | 0/1 | 1/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| Enterocolitis infectiousInfections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 1/4 | 0/25 | 0/1 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| Respiratory tract infectionInfections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 1/4 | 0/25 | 0/1 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| SepsisInfections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 1/4 | 0/25 | 0/1 | 0/7 | 0/2 | 0/1 | 0/1 | 0/2 | 0/9 |
| Event | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AstheniaGeneral disorders | 0/4 | 0/3 | 1/3 | 1/3 | 1/4 | 1/4 | 2/25 | 0/1 | 1/7 | 0/2 | 0/1 | 1/1 | 1/2 | 0/9 |
| FatigueGeneral disorders | 1/4 | 1/3 | 0/3 | 0/3 | 0/4 | 0/4 | 4/25 | 0/1 | 1/7 | 0/2 | 1/1 | 0/1 | 0/2 | 0/9 |
| Amylase increasedInvestigations | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 2/4 | 4/25 | 0/1 | 1/7 | 0/2 | 1/1 | 0/1 | 0/2 | 0/9 |
| AnaemiaBlood and lymphatic system disorders | 2/4 | 1/3 | 1/3 | 1/3 | 0/4 | 1/4 | 6/25 | 0/1 | 3/7 | 2/2 | 0/1 | 0/1 | 0/2 | 3/9 |
| NauseaGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 1/3 | 1/4 | 2/4 | 10/25 | 0/1 | 3/7 | 0/2 | 1/1 | 0/1 | 0/2 | 2/9 |
| VomitingGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 2/4 | 4/25 | 0/1 | 1/7 | 0/2 | 1/1 | 0/1 | 0/2 | 1/9 |
| Upper respiratory tract infectionInfections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 1/4 | 1/4 | 1/25 | 0/1 | 0/7 | 0/2 | 0/1 | 1/1 | 1/2 | 0/9 |
| Urinary tract infectionInfections and infestations | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 1/25 | 0/1 | 1/7 | 0/2 | 1/1 | 0/1 | 1/2 | 0/9 |
| PruritusSkin and subcutaneous tissue disorders | 0/4 | 0/3 | 0/3 | 0/3 | 1/4 | 0/4 | 2/25 | 0/1 | 0/7 | 0/2 | 1/1 | 0/1 | 0/2 | 1/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 1/25 | 0/1 | 1/7 | 0/2 | 1/1 | 0/1 | 0/2 | 1/9 |
The Full Analysis Set (FAS) included all patients who received at least 1 dose of HMPL-523.
| Age, Continuous(years) | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 69.8 ± 11.12 | 55.0 ± 7.00 | 57.7 ± 30.09 | 53.0 ± 21.07 | 56.3 ± 21.72 | 58.8 ± 16.28 | 42.8 ± 17.83 | 76.0 | 65.1 ± 7.76 | 75.5 ± 2.12 | 93.0 | 67.0 | 69.5 ± 7.78 | 64.4 ± 14.53 | 56.1 ± 19.00 |
| Sex: Female, Male(Participants) | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 1 | 1 | 1 | 2 | 10 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 27 |
| Male | 4 | 2 | 2 | 2 | 3 | 2 | 15 | 0 | 5 | 1 | 0 | 0 | 1 | 5 | 42 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 4 | 2 | 3 | 2 | 4 | 4 | 19 | 1 | 6 | 2 | 1 | 1 | 2 | 8 | 59 |
| Black or African American | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Multiple | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation Stage: HMPL-523 100 mg QD | Dose Escalation Stage: HMPL-523 200 mg QD | Dose Escalation Stage: HMPL-523 400 mg QD | Dose Escalation Stage: HMPL-523 600 mg QD | Dose Escalation Stage: HMPL-523 700 mg QD | Dose Escalation Stage: HMPL-523 800 mg QD | Dose Expansion Stage: HL | Dose Expansion Stage: CLL | Dose Expansion Stage: CLL-post BTK | Dose Expansion Stage: FL | Dose Expansion Stage: MZL | Dose Expansion Stage: LPL/WM | Dose Expansion Stage: MCL | Dose Expansion Stage: PTCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 4 | 14 |
| Not Hispanic or Latino | 2 | 1 | 2 | 2 | 4 | 3 | 22 | 1 | 5 | 2 | 1 | 1 | 2 | 4 | 52 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Feb 2025, 65 months.
Results were first posted in Feb 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sovleplenib